Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
In spite of the clinical usefulness of cisplatin (CDDP), there are many occasions in which it is difficult to continue the administration of CDDP due to its nephrotoxicity and neurotoxicity. We examined the incorporation of CDDP into polymeric micelles to see if this allowed the resolution of these disadvantages. Cisplatin was incorporated into polymeric micelles through the polymer-metal complex formation between polyethylene glycol poly(glutamic acid) block copolymers and CDDP (NC-6004). The pharmacokinetics, pharmacodynamics, and toxicity studies of CDDP and NC-6004 were conducted in rats or mice. The particle size of NC-6004 was approximately 30 nm, with a narrow size distribution. In rats, the area under the curve and total body clearance values for NC-6004 were 65-fold and one-nineteenth the values for CDDP (P<0.001 and 0.01, respectively). In MKN-45-implanted mice, NC-6004 tended to show antitumour activity, which was comparable to or greater than that of CDDP. Histopathological and biochemical studies revealed that NC-6004 significantly inhibited the nephrotoxicity of CDDP. On the other hand, blood biochemistry revealed transient hepatotoxicity on day 7 after the administration of NC-6004. Furthermore, rats given CDDP showed a significant delay (P<0.05) in sensory nerve conduction velocity in their hind paws as compared with rats given NC-6004. Electron microscopy in rats given CDDP indicated the degeneration of the sciatic nerve, but these findings were not seen in rats given NC-6004. These results were presumably attributable to the significantly reduced accumulation of platinum in nerve tissue when NC-6004 was administered (P<0.05). NC-6004 preserved the antitumour activity of CDDP and reduced its nephrotoxicity and neurotoxicity, which would therefore seem to suggest that NC-6004 could allow the long-term administration of CDDP where caution against hepatic dysfunction must be exercised.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“NC-6004 exhibited stable micelles in solution and slowly released cisplatin from the micelle for over 150 h in physiological saline. NC-6004 exhibited a narrow size distribution in solution with a size of 28 nm and loading of cisplatin in NC-6004 was up to 39% LC [153].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [153]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A similar polymeric micelle formulation where CDDP was coordinated with PEG-b-P(Glu) [153] evolved into a clinically evaluated polymeric micelle drug, NC-6004 which is described below in Section 5.3.”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [153]
The cited source says what the claim attributes to it.
In the citing paper
“Originally developed by Kataoka’s group and NanoCarrier Co., Ltd., NC-6004 is a cisplatin-containing polymeric micelle formed via coordination of platinum drug with the P(Glu) segment of the PEG-b-P(Glu) block copolymer (PEG: 12,000 g/mol and P(Glu): 6,000 g/mol) [153].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [153]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Self-citationTumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Self-citationMaeda, H. (2001) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(00)00013-3 · Cited by 2,495 · cited 1×
“…polymers or nanoparticles, which are less prone to leak from intact vasculature, and which can be retained in solid tumour tissue for a longer time (enhanced permeability and retention effect (EPR) effect) (Matsumura and Maeda, 1986; Maeda and Matsumura, 1989; Maeda, 2000, 2001).”
BackgroundAmphipathic polyethyleneglycols effectively prolong the circulation time of liposomes
Klibanov, A. L., Maruyama, K., Torchilin, V. P., & Huang, L. (1990) · FEBS Letters · doi:10.1016/0014-5793(90)81016-h · Cited by 2,027 · cited 1×
“…93, 678 – 687 & 2005 Cancer Research UK All rights reserved 0007 – 0920/05 $30.00 www.bjcancer.com T ra n sla tio n a l T h e ra p e u tic s the reticuloendothelial system (RES) and to enhance the blood retention profile (Klibanov et al, 1990, 1991; Allen, 1994; Gabizon etal, 1996; Lasic, 1996).”
BackgroundInfluentialdu Bois, A. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg036 · Cited by 1,113 · cited 1×
“Consequently, these analogues are becoming the standard drugs for ovarian cancer (du Bois et al, 2003) and colon cancer (Cassidy et al, 2004).”
BackgroundNovel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice.
Nishiyama, N., Okazaki, S., Cabral, H., Miyamoto, M., Kato, Y., Sugiyama, Y., Nishio, K., Matsumura, Y., & Kataoka, K. (2003) · PubMed · Cited by 710
Self-citation(1998) · British Journal of Cancer · doi:10.1038/bjc.1998.1 · Cited by 654
Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
Matsumura, Y., Hamaguchi, T., Ura, T., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., Okusaka, T., Ueno, H., Ikeda, M., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602204 · Cited by 623 · cited 1×
“The Phase I clinical trial of adriamycin-incorporating polymeric micelles has been completed (Matsumura et al, 2004).”
BackgroundSelf-citationHamaguchi, T., Matsumura, Y., Suzuki, M., Shimizu, K., Goda, R., Nakamura, I., Nakatomi, I., Yokoyama, M., Kataoka, K., & Kakizoe, T. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602479 · Cited by 565
Self-citationCassidy, J., Tabernero, J., Twelves, C., Brunet, R., Butts, C., Conroy, T., Debraud, F., Figer, A., Grossmann, J., Sawada, N., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.069 · Cited by 525 · cited 1×
“Consequently, these analogues are becoming the standard drugs for ovarian cancer (du Bois et al, 2003) and colon cancer (Cassidy et al, 2004).”
Background
Cited by
Items 301–400 of 432
Thangjam, P. D., & Lonibala, R. (2009) · Journal of Chemical & Engineering Data · doi:10.1021/je900583g · Cited by 10
Wang, Z., Li, Y., Zhang, T., Li, H., Yang, Z., & Wang, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.632877 · Cited by 9
“Preparation and Characterization of CISP-NPs Preparation of CISP-NPs CISP-NPs were prepared according to the procedure described previously with slight modifications (Nishiyama et al., 2003; Uchino et al., 2005).”
MethodPhysiologically-Based Modeling and Interspecies Prediction of Cisplatin Pharmacokinetics
Zang, X., & Kagan, L. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.10.022 · Cited by 8
Liu, J.-R., Wang, X., Cui, Y., Lu, J., He, Z., Xu, Y., Li, R., Xu, G., Gao, L., Fan, X., et al. (2025) · Clinical & Experimental Metastasis · doi:10.1007/s10585-025-10367-w · Cited by 8
“…AKT-mediated inhibition of GSK3β decreases the phosphorylation and degradation of β-catenin, leading to its cytoplasmic accumulation and nuclear translocation, where it activates EMT-related genes (e.g., Snail, CD44), promoting tumor of cisplatin at 5 mg/kg BW for the in vivo model [ 44, 45].”
Tumor Vasculature, EPR Effect, and Anticancer Nanomedicine: Connecting the Dots
Taurin, S., Nehoff, H. L., van Aswegen, T., & Greish, K. F. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7876-8_8 · Cited by 10
“For example, nanoconstructs of cis-platinum have reduced toxicity in the kidney compared to the free drug but result in a doselimiting liver toxicity [ 177 ].”
Stoyanova, E., Petrov, P. D., Karadjova, I. B., Momekov, G., & Koseva, N. S. (2017) · Polymer Journal · doi:10.1038/pj.2017.29 · Cited by 8
Nanopharmacy: Exploratory Methods for Polymeric Materials
Bansal, K. K., Sasso, L., Makwana, H., Awwad, S., Brocchini, S., & Alexander, C. (2016) · Wiley eBooks · doi:10.1002/9783527800681.ch10 · Cited by 9
NC-6004, a novel cisplatin nanoparticle, in combination with pembrolizumab for head and neck cancer
Osada, A. (2019) · Integrative Clinical Medicine · doi:10.15761/icm.1000147 · Cited by 8
Kishimoto, S., Fujitani, N., OHNISHI, T., AOKI, H., SUZUKI, R., & Fukushima, S. (2017) · Anticancer Research · doi:10.21873/anticanres.12053 · Cited by 8
Sakai‐Kato, K., Nanjo, K., Kusuhara, H., Nishiyama, N., Kataoka, K., Kawanishi, T., Okuda, H., & Goda, Y. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00234 · Cited by 8
Self-citationTang, J., Wang, X.-Q., Wang, T., Chen, F., & Zhou, J. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.09.016 · Cited by 8
“Other two samples of poly (amino acid) polymeric micelles system were PEG-poly(glutamic acid) (Koizumi et al., 2006; Uchino et al., 2005) and PEG-poly(aspartic acid) (Yokoyama et al.”
MethodSelf‐Folding Macromolecular Drug Carrier for Cancer Imaging and Therapy
Gao, S., Miura, Y., Sumiyoshi, A., Ohno, S., Ogata, K., Nomoto, T., Matsui, M., Honda, Y., Suzuki, M., Iiyama, M., et al. (2023) · Advanced Science · doi:10.1002/advs.202304171 · Cited by 8
Self-citationEnhanced Vascular Permeability in Solid Tumors: A Promise for Anticancer Nanomedicine
Taurin, S., & Greish, K. F. (2013) · Cancer metastasis · doi:10.1007/978-94-007-6028-8_4 · Cited by 11
Uivaroşi, V., Olar, R., & Badea, M. (2017) · InTech eBooks · doi:10.5772/intechopen.68306 · Cited by 7
“The in vitro and in vivo preclinical assays evidenced a complete tumor regression as well as a low nephrotoxicity and neurotoxicity in C26 murine colon carcinoma cell [27].”
BackgroundNew Oxaliplatin-Pyrophosphato Analogs with Improved In Vitro Cytotoxicity
Barbanente, A., Iacobazzi, R. M., Azzariti, A., Hoeschele, J. D., Denora, N., Papadia, P., Pacifico, C., Natile, G., & Margiotta, N. (2021) · Molecules · doi:10.3390/molecules26113417 · Cited by 7
“Severe side effects, such as nephro-, neuro-, and oto-toxicity, limit its use [5,6].”
BackgroundTheranostic Polymeric Micelles for Cancer Imaging and Therapy
Huang, G., Khemtong, C., Bey, E. A., Boothman, D. A., Sumer, B. D., & Gao, J. (2012) · Nanostructure science and technology · doi:10.1007/978-1-4614-2305-8_12 · Cited by 7
Synthetic–Biological Hybrid Polymers
Börner, H. G., & Lutz, J. (2012) · Elsevier eBooks · doi:10.1016/b978-0-444-53349-4.00173-4 · Cited by 7
PEO-Modified Poly(L -Amino Acid) Micelles for Drug Delivery
Xiong, X.-B., Aliabadi, H. M., & Lavasanifar, A. (2006) · CRC Press eBooks · doi:10.1201/9781420006636-18 · Cited by 7
Renette, T., Librizzi, D., Endres, T., Merkel, O. M., Beck‐Broichsitter, M., Bege, N., Petersen, H., Curdy, C., & Kissel, T. (2012) · Macromolecular Bioscience · doi:10.1002/mabi.201100499 · Cited by 7
Toxicology of Engineered Metal Nanoparticles
Bernardini, G., Cattaneo, A. G., Sabbioni, E., Gioacchino, M. D., Chiriva‐Internati, M., & Gornati, R. (2009) · Wiley eBooks · doi:10.1002/9780470744307.gat240 · Cited by 7
Polymer Conjugate as the New Promising Drug Delivery System for Combination Therapy against Cancer
Hu, Q., Zhang, Y., Mukerabigwi, J. F., Wang, H., & Cao, Y. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266280603240321064308 · Cited by 6
DNA synthesis inhibitors for the treatment of gastrointestinal cancer
Yasui, H., Tsurita, G., & Imai, K. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.958074 · Cited by 6
“showed that NC-6004 had significantly lower toxicity than cisplatin and greater antitumor activity [98].”
BackgroundFranskevych, D., Prylutska, S., Grynyuk, І. І., Grebinyk, D. M., & Matyshevska, O. (2015) · Experimental Oncology · doi:10.31768/2312-8852.2015.37(3):187-191 · Cited by 6
Preclinical to Clinical Development of Nanomedicines
Svenson, S. (2014) · Frontiers in nanobiomedical research · doi:10.1142/9789814520652_0058 · Cited by 7
van Gaal, E. V. B., & Crommelin, D. J. A. (2015) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-319-16241-6_2 · Cited by 12
Kudo, M., Yamamoto, Y., Koga, Y., Hamaguchi, T., Akimoto, T., Yasunaga, M., & Matsumura, Y. (2016) · Molecular and Clinical Oncology · doi:10.3892/mco.2016.1070 · Cited by 6
“In agreement with a previous study (8), the cytotoxic effect of NC-6004 was between 6.1-and 14.0-fold lower compared with that of CDDP.”
InfluentialSelf-citationJang, Y., Bellier, N., Canlas, K. K. V., Lee, J. Y., Kim, Y., Park, H., & Moon, J. J. (2026) · Nano Convergence · doi:10.1186/s40580-026-00545-1 · Cited by 5
“…mechanical stability, tunable size, and programmable release kinetics, with hydrophobic cores for encapsulating metal complexes or metal-based nanocrystals and hydrophilic coronas for steric stabilization, prolonged circulation, and ligand conjugation sites to enable active targeting [257–262].”
Implementation of Nanoparticles in Cancer Therapy
Bayır, E., Bilgi, E., & Şendemir, A. (2014) · Advances in chemical and materials engineering book series · doi:10.4018/978-1-4666-5824-0.ch018 · Cited by 5
Farzi, G., & Gheysipour, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824345-9.00010-6 · Cited by 7
Chen, H., Lo, Y., Wu, P., Lo, P.-C., & Wang, L. (2017) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2017.05.034 · Cited by 5
Zhang, L., Zhang, Y., Yin, G., Zhao, H., Ma, W., & Gao, F. (2018) · Imaging, Manipulation, and Analysis of Biomolecules, Cells, and Tissues · doi:10.1117/12.2287056 · Cited by 5
“Traditional methods to such research would sacrifice subsets of animals (often mice) at different time points to collect plasma or tumor and measure the drug concentration in each [8-10] .”
MethodZhil’tsova, E. P., Ibatullina, M. R., Safina, N. K., & Zakharova, L. Y. (2022) · Russian Journal of General Chemistry · doi:10.1134/s1070363222040089 · Cited by 5
Amphiphilic Block Copolymer Based Nanocarriers for Drug and Gene Delivery
Xiong, X.-B., & Lavasanifar, A. (2011) · Fundamental biomedical technologies · doi:10.1007/978-94-007-1248-5_10 · Cited by 5
Yin, R., Gou, S., Sun, Y., & Liu, X. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.12.056 · Cited by 5
Inorganic Polymers for Potential Medicinal Applications
Valente, A., Precker, R. L. M., & Hey‐Hawkins, E. (2019) · Wiley eBooks · doi:10.1002/9783527819140.ch9 · Cited by 5
Polymeric Micelles Employing Platinum(II) Linker for the Delivery of the Kinase Inhibitor Dactolisib
Shi, H., Lou, B., van Steenbergen, M. J., Sijbrandi, N. J., Hennink, W. E., & Kok, R. J. (2019) · Particle & Particle Systems Characterization · doi:10.1002/ppsc.201900236 · Cited by 5
Barbanente, A., Ditaranto, N., Laghezza, A., Tortorella, P., Intini, F. P., Pacifico, C., Natile, G., & Margiotta, N. (2023) · Dalton Transactions · doi:10.1039/d3dt00734k · Cited by 5
Du, J., & Lu, H. (2012) · Wiley eBooks · doi:10.1002/0471440264.pst547 · Cited by 5
Dual Trigger Crosslinked Micelles Based Polyamidoamine for Effective Paclitaxel Delivery
Kong, K. V. (2014) · Journal of Nanomedicine & Nanotechnology · doi:10.4172/2157-7439.1000212 · Cited by 4
Pharmacokinetics and Pharmacodynamics ( PK / PD ) of Bionanomaterials
Liu, E., Zhang, M., & Huang, Y. (2016) · Wiley eBooks · doi:10.1002/9783527694396.ch1 · Cited by 10
Kaymak, E., Karabulut, D., Öztürk, E., Akın, A. T., & Yakan, B. (2021) · International Journal of Morphology · doi:10.4067/s0717-95022021000200659 · Cited by 4
Lopez‐Sanchez, A., Chédotal, H., Muthuramalingam, R. P. K., Thomas, M., Yau, J. N. N., Sahoo, P. R., Policar, C., Batteux, F., Medjoubi, K., Somogyi, A., et al. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202501847 · Cited by 4
Nanocarrier Delivery of Cisplatin and its Patent Studies
Kumar, M., Sharma, S., Bhatnagar, P., Tejaswi, & Banik, B. K. (2024) · Current Nanomedicine · doi:10.2174/0124681873332471241022152313 · Cited by 3
Poly[platinum( iv )-alt-PEI]/Akt1 shRNA complexes for enhanced anticancer therapy
Zhang, J.-L., Gong, J., Xing, L., Cui, P., Qiao, J.-B., He, Y., Lyu, J.-Y., Che, S., Jin, T., & Jiang, H. (2016) · RSC Advances · doi:10.1039/c6ra16435h · Cited by 3
Neoh, K. G., Lu, S., Kang, E. T., Mahendran, R., & Chiong, E. (2016) · ACS symposium series · doi:10.1021/bk-2016-1224.ch009 · Cited by 3
Wang, H., Han, M., & Han, Z. (2012) · InTech eBooks · doi:10.5772/33860 · Cited by 3
“It can be used for finding new ligands, such as enzyme inhibitors, receptor agonists and antagonists, to target proteins (Hariri et al., 2008; Pasqualini et al., 1995; Perea et al., 2004; Ruoslahti, 1996; Uchino et al., 2005).”
BackgroundSelf-Assembled Polymeric Nanomicelles as Delivery Carriers for Antitumor Drug Camptothecin
Zeng, J., Yu, J., Huang, J., & Chang, P. R. (2012) · Journal of Dispersion Science and Technology · doi:10.1080/01932691.2011.562407 · Cited by 3
Nanomedicine: Size-Related Drug Delivery Applications, Including Periodontics and Endodontics
Ng, X. W., Mundargi, R. C., & Venkatraman, S. S. (2015) · Springer eBooks · doi:10.1007/978-3-319-13575-5_5 · Cited by 4
Effects of block copolymer micelles on the pharmacokinetics of encapsulated drugs
Binkhathlan, Z., & Lavasanifar, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816200-2.00017-7 · Cited by 7
Sasai, M., Sakura, K. L., Matsuda, T., & Uyama, H. (2021) · Polymers · doi:10.3390/polym13111803 · Cited by 3
“For example, micellization of CDDP using polyethylene glycol (PEG) has been reported as a method for reducing the nephrotoxicity of CDDP while exerting an equivalent antitumor effect [3].”
MethodPLGA Nanoparticles for Oral Delivery: Nephrotoxicity and Pharmacokinetic Studies
Singh, N., Mishra, N., Raza, K., & Parashar, P. (2022) · Springer eBooks · doi:10.1007/978-3-030-83395-4_18 · Cited by 3
Yin, X., Wang, Q., Zhang, M., Zhang, C., Chen, Q., Li, H., Zhao, Y., Wang, Y., Wang, J., Zhang, L., et al. (2026) · Smart Molecules · doi:10.1002/smo2.70055 · Cited by 2
Recent Advancements in Nanotechnology for Oral Cancer: a Review
Talele, D. R., & Patel, D. H. (2020) · Current Drug Therapy · doi:10.2174/1574885515999201021165906 · Cited by 2
NANO-DRUG DESIGNING STRATEGIES AND TARGETED APPLICATIONS FOR CANCER TREATMENT
Noor, U., Ahmed, T., Khalid, S., Khalid, M., Sharif, A., Noor, I., Waheed, W., Jamil, I., Zafar, Z. S., & Kulsum, U. (2023) · International Journal of Pharmacy & Integrated Health Sciences · doi:10.56536/ijpihs.v4i1.68 · Cited by 2
“preclinical trials (24-26) which claimed that cisplatin toxicity can be controlled if not eliminated by administering cisplatin incorporated micelles ad improved therapeutic indices.”
BackgroundRana, S., Shahid, S., Iqbal, M. S., Arshad, A., & Khan, D. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e31057 · Cited by 2
RetractedNanomedicine in Cancer Treatment
Kim, J., & Cho, M. (2014) · Wiley eBooks · doi:10.1002/9781118856017.ch10 · Cited by 2
Multifunctional Polymeric Micelles for Drug Delivery and Therapeutics
Sawdon, A. J., & Peng, C. (2013) · Wiley eBooks · doi:10.1002/9781118636299.ch15 · Cited by 2
Review of phase I study of NC-6004, a cisplatin-incorporated polymeric micelle, in United Kingdom
Shimizu, T., & Kato, Y. (2009) · Drug Delivery System · doi:10.2745/dds.24.45 · Cited by 2
Uptake of CDDP-containing Polymeric Micelles by Cells Using Particle Induced X-Ray Emission
Mizuno, K., Konishi, T., Oikawa, M., Hiroyuki, I. S. O., Ishikawa, T., Imaseki, H., & Uesaka, M. (2010) · Journal of Radiation Research · doi:10.1269/jrr.10074 · Cited by 2
Terakawa, A., Ishii, K., Matsuyama, S., Kikuchi, Y., Kawamura, T., Takahashi, Y., Miura, Y., Karahashi, M., Kusano, K., Yamazaki, H., et al. (2014) · International Journal of PIXE · doi:10.1142/s0129083514500053 · Cited by 2
The initiatives for regulatory science researches of nanomedicines
Harashima, H., Akita, H., Sakai‐Kato, K., Ishii, T., Matsumura, Y., & Kataoka, K. (2014) · Drug Delivery System · doi:10.2745/dds.29.217 · Cited by 2
Self-citationPoly(Amino Acid) Nanoparticles as a Promising Tool for Anticancer Therapeutics
Abdelaziz, H. M., Abdelmoneem, M. A., Abd-Elsalam, K., Freag, M. S., Elkhodairy, K. A., & Elzoghby, A. O. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816963-6.00009-1 · Cited by 6
Biological barriers to cancer drug delivery, efficacy and cancer models
Madkour, L. H. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-819777-6.00018-4 · Cited by 2
One‐Pot Synthesis of New Organometallic Compounds with Platinum‐Carbon Bond
Barbanente, A., Margiotta, N., Pacifico, C., Intini, F. P., & Natile, G. (2019) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.201901192 · Cited by 2
Nanotheranostics and biocompatibility
Sharma, I., & Bhattacharjee, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822878-4.00003-1 · Cited by 2
Nanomedicine Magic Bullet for Human Cancer
Patnaik, S. (2016) · IGI Global eBooks · doi:10.4018/978-1-5225-0549-5.ch014 · Cited by 4
Tomar, N., Hashmi, M. A., & Hashmi, A. A. (2020) · Wiley eBooks · doi:10.1002/9781119640868.ch12 · Cited by 3
Synthesis, characterisation and multi-modal intracellular mapping of cisplatin nano-conjugates
Leventi, A. A., Braddick, H. J., Billimoria, K., Wallace, G. Q., Infante, H. G., Tomkinson, N. C. O., Faulds, K., & Graham, D. (2023) · Chemical Communications · doi:10.1039/d3cc00925d · Cited by 2
EVALUATION OF THE UPTAKE OF CDDP-CONTAINING POLYMERIC MICELLES IN SINGLE PANCREATIC CANCER CELLS
Mizuno, K., Uesaka, M., Matsuyama, S., Ito, Y., Ishii, K., & Yamazaki, H. (2010) · International Journal of PIXE · doi:10.1142/s012908351000194x · Cited by 2
Stimuli-Sensitive Platinum-Based Anticancer Polymer Therapeutics: Synthesis and Evaluation In Vitro
Běhalová, K., Studenovský, M., Kotalík, K., Konefał, R., Kovář, M., & Etrych, T. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17111433 · Cited by 1
“NC-6004 significantly extended the plasma half-life of cisplatin and demonstrated reduced kidney and nerve toxicity in preclinical models, while maintaining robust anticancer activity [16].”
Alginate and hyaluronic acid-based prodrugs: Synthesis, properties, and biomedical applications
Fattahi, N., Linh, N. V., Khan, F., Kim, Y.-M., Kim, T.-H., & Jung, W. (2026) · Reactive and Functional Polymers · doi:10.1016/j.reactfunctpolym.2026.106734 · Cited by 1
Rajesh, S., Ho, G., Fernando, R., Gan, P. Y., Wu, J., Zhai, J., Ooi, J. D., Drummond, C. J., & Tran, N. L. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18050614 · Cited by 1
“Several formulations, such as polymeric micelles (NC-6004) [9], polymer conjugates (AP5280) [10], and liposomes (B103, SPI-077, and Lipoplatin) [11,12], have demonstrated promising results in preclinical studies.”
Kumar, A. R., Kamath, A. J., Joseph, A. A., Sudheesh, M. S., Chauhan, A. S., Sethi, G., & Nath, L. R. (2026) · Cancer Nanotechnology · doi:10.1186/s12645-026-00395-w · Cited by 1
“Similarly, Cisplatin encapsulated micelles (NC-6004) confirmed an 8-fold increase in Cmax compared to free Cis-platin (Uchino et al. 2005).”
Emerging biodegradable nanomaterials for innovative tumor immunotherapy
Dong, R., Ding, S., Song, B., Zhou, Q., Tian, G., Yong, Y., & Xie, J. (2026) · Journal of Materials Chemistry B · doi:10.1039/d6tb00909c · Cited by 1
Tseng, C., Wu, Y.-H., Yu, S.-W., Yang, K., & Lin, F. (2009) · World Congress on Medical Physics and Biomedical Engineering, September 7 - 12, 2009, Munich, Germany · doi:10.1007/978-3-642-03887-7_100 · Cited by 1
Nanoterapias oncológicas: aplicaciones actuales y perspectivas futuras
Lollo, G., Rodríguez, G. R., Torres, D., & Alonso, M. J. (2011) · Anales de la Real Academia Nacional de Farmacia · Cited by 1
Clinical development of anticancer agents incorporating micelles in oncological treatment
Matsumura, Y. (2013) · Drug Delivery System · doi:10.2745/dds.28.215 · Cited by 1
Self-citationContrast enhancement of iohexol-cisplatin-gelatin complex under computed tomography imaging
Liu, W.-H., Wang, Y.-K., Wu, C.-C., Deng, W., Lin, K.-H., Lo, W., & Tseng, C. (2013) · Journal of Polymer Engineering · doi:10.1515/polyeng-2013-0223 · Cited by 1
A clinical trial can determine the course of DDS development
Matsumura, Y. (2014) · Drug Delivery System · doi:10.2745/dds.29.39 · Cited by 1
Self-citationTranslational research of DDS based on polymeric micelles
Nishiya, T., Matsumura, Y., & Kataoka, K. (2011) · Folia Pharmacologica Japonica · doi:10.1254/fpj.137.75 · Cited by 1
Self-citationCooper, D. L. (2016) · Digital Commons - East Tennessee State University (East Tennessee State University) · Cited by 2
Nanomedicine Magic Bullet for Human Cancer
Patnaik, S. (2014) · Advances in chemical and materials engineering book series · doi:10.4018/978-1-4666-6363-3.ch009 · Cited by 1
Tanaka, P. P., Torres, M. F., & Tenório, S. B. (2012) · Brazilian Journal of Anesthesiology · doi:10.1016/s0034-7094(12)70120-4 · Cited by 1
Nanotechnology for Diagnosis, Imaging, and Treatment of Head and Neck Cancer
Ebrahimi, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-69859-1_4 · Cited by 2
Protective Effect of Polyethylene Glycol (PEG) 3350 on a Cisplatin-Induced Rat Model of Neuropathy
Gönüllü, E., Dağıstan, G., Erdoğan, M. A., & Erbaş, O. (2022) · International Journal of Pharmacology · doi:10.3923/ijp.2022.1359.1365 · Cited by 1
Singh, R. P., Yadav, B., Chauhan, M., Shekhar, S., Nayak, A. K., Dutt, R., & Sonali (2022) · Current Protein and Peptide Science · doi:10.2174/1389203724666221102164756 · Cited by 1
Role of Block Co-Polymers in Drug Delivery
Panda, P. K., Raikwar, S., Bidla, P. D., Rathee, S., & Jain, S. (2023) · Springer eBooks · doi:10.1007/978-981-99-6917-3_2 · Cited by 1
Polymeric Nanocarriers for Cancer Therapy
Mi, P., & Nishiyama, N. (2014) · Advances in delivery science and technology · doi:10.1007/978-3-319-08084-0_3 · Cited by 1
Self-citationTranslational research of drug delivery system and the investigational new drug application for DDS
Matsumura, Y. (2007) · Drug Delivery System · doi:10.2745/dds.22.60 · Cited by 1
Self-citationPolysaccharide-based Polyion Complex Micelles as New Delivery Systems for Hydrophilic Cationic Drugs
Soliman, G. M. (2009) · doi:10.71781/4636 · Cited by 3
Arginine-Rich Ionic Complementary Peptides and Their Drug Delivery Potential
Wan, Z. (2013) · UWSpace (University of Waterloo) · Cited by 1
Π-π Stacked Polymeric Micelles as Carriers of Anticancer Therapeutics for Hematological Malignancies
Varela-Moreira, A. (2020) · Utrecht University Repository (Utrecht University) · doi:10.33540/145 · Cited by 2
Miller, K., & Satchi‐Fainaro, R. (2008) · Wiley eBooks · doi:10.1002/9780470048672.wecb462 · Cited by 1
POLYMERIC MICELLES AS IMAGING AGENTS AND DRUG DELIVERY SYSTEMS
Zhao, J., & Li, C. (2013) · Wiley eBooks · doi:10.1002/9781118356845.ch12
Preclinical evaluation of a novel drug delivery system for cisplatin
Venugopal, B. (2012) · Enlighten: Theses (The University of Glasgow)
Nanomedicinas: lo esencial es invisible...al microscopio óptico
Romero, E. L., & Morilla, M. J. (2013) · Americanae (AECID Library)
Tanaka, P. P., Torres, M. F., & Tenório, S. B. (2012) · Brazilian Journal of Anesthesiology · doi:10.1590/s0034-70942012000200008
Development of Novel Models to Study Ovarian Cancer Stem Cells.
Ojeda, B., & Vanesa, D. (2014) · Deep Blue (University of Michigan)
Carrier-Mediated and Targeted Cancer Drug Delivery
Zamboni, W. C., & La-Beck, N. M. (2011) · Humana Press eBooks · doi:10.1007/978-1-61779-397-4_21
Matsumura, Y. (2010) · Oleoscience · doi:10.5650/oleoscience.10.25
Self-citation
Metadata
- Authors
- Uchino, H., Matsumura, Y., Negishi, T., Koizumi, F., Hayashi, T., Honda, T., Nishiyama, N., Kataoka, K., Naito, S., & Kakizoe, T.
- Affiliations
- National Cancer Center Hospital East (JP)
- NanoCarrier (Japan) (JP)
- Fukushima Medical University (JP)
- The University of Tokyo (JP)
- Kyushu University (JP)
- National Cancer Centre Japan (JP)
- Corresponding author
- Matsumura, Y
- Venue
- British Journal of Cancer
- Published
- 2005-09
- Volume
- 93
- Issue
- 6
- Pages
- 678-687
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC2361620
- OpenAlex
- W1974920077
- Cited by
- 430
- References
- 37
- Citations by year
- 2026: 10 · 2025: 7 · 2024: 9 · 2023: 12 · 2022: 20 · 2021: 22 · 2020: 21 · 2019: 20 · 2018: 9 · 2017: 34 · 2016: 27 · 2015: 35 · 2014: 39 · 2013: 32 · 2012: 29
- FWCI
- 5.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Ministry of Health, Labour and Welfare
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Chemotherapy-induced organ toxicity mitigation
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Keywords
- cisplatin, polymeric micelles, nephrotoxicity, neurotoxicity, hepatotoxicity, sensory nerve conduction velocity, antitumour activity, pharmacokinetics, drug toxicity reduction
- MeSH terms
- Animals, Antineoplastic Agents, Body Weight, Brain, Cisplatin, Drug Carriers, Female, Humans, Kidney, Kidney Diseases, Liver, Mice, Inbred BALB C, Mice, Nude, Micelles, Polyethylene Glycols, Tumor Cells, Cultured, Rats, Sprague-Dawley, Neurotoxicity Syndromes, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.